Clinical Trial Update: Long-term Follow-up of Fingolimod Phase II Study Patients [Phase 4]

View source ↗

Summary

Long-term follow-up results from fingolimod in a Phase II study for relapsing forms of multiple sclerosis have been reported (Phase 4 update; completed; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2017-03-23